Pi­ra­mal goes or­ganic for pharma growth

BioSpectrum (India) - - COMPANY NEWS -

Pi­ra­mal En­ter­prises Ltd

(PEL) is look­ing at grow­ing or­gan­i­cally in phar­ma­ceu­ti­cal seg­ment to move up the value chain and ex­pand­ing in ser­vices like an­ti­body drug con­ju­gates, injectables and drug dis­cov­ery, ac­cord­ing to its an­nual re­port.

In the last two years, the pharma seg­ment de­ployed around half a bil­lion dol­lar of cap­i­tal for fu­ture growth through var­i­ous or­ganic as well as in­or­ganic ini­tia­tives. PEL is now look­ing at in­vest­ments for ex­pan­sion of the man­u­fac­tur­ing and ser­vice de­liv­er­ing ca­pa­bil­i­ties in niche ar­eas of ADC, injectables, in­hala­tion anaesthesia and dis­cov­ery ser­vices.

It also plans to launch first generic ver­sion of Des­flu­rane, the latest gen­er­a­tion in­hala­tion anaesthesia prod­uct, in FY18. Last year, the com­pany added two niche dif­fer­en­ti­ated prod­uct port­fo­lios in global pharma prod­ucts busi­ness.

It has ac­quired a port­fo­lio of five branded prod­ucts in the in­jectable anaesthesia and pain man­age­ment area from Janssen and a port­fo­lio of in­trathe­cal spas­tic­ity and two pain man­age­ment prod­ucts un­der de­vel­op­ment from Mallinck­rodt LLC.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.